Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis

Nature Medicine

Volumn 21, Issue 10, 2015, Pages 1190-1198

  Zhang, Jiyuan ^a   Dominguez Sola, David ^a,b   Hussein, Shafinaz ^a,e   Lee, Ji Eun ^c   Holmes, Antony B ^a   Bansal, Mukesh ^a   Vlasevska, Sofija ^a   Mo, Tongwei ^a   Tang, Hongyan ^a   Basso, Katia ^a,d   Ge, Kai ^c   Dalla Favera, Riccardo ^a,d   Pasqualucci, Laura ^a,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; PROTEIN BCL 2; DNA BINDING PROTEIN; MLL2 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL MATURATION; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; FEMALE; FOLLICULAR LYMPHOMA; GENE DELETION; GENE EXPRESSION PROFILING; GENE LOSS; GENE OVEREXPRESSION; GERMINAL CENTER; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; INCIDENCE; KMT2D GENE; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOMAGENESIS; MALE; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL; TUMOR SUPPRESSOR GENE; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DNA METHYLATION; GENE SILENCING; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE SILENCING; GERMINAL CENTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MUTATION, MISSENSE; NEOPLASM PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84944161087     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3940     Document Type: Article

References (75)

1. Shaffer III, A.L., Young, R.M. & Staudt, L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30, 565-610 (2012).
2. Basso, K. & Dalla-Favera, R. Germinal centers and B cell lymphomagenesis. Nat. Rev. Immunol. 15, 172-184 (2015).
3. Morin, R.D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
4. Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B cell lymphoma. Nature 471, 189-195 (2011).
5. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B cell lymphoma. Nat. Genet. 43, 830-837 (2011).
6. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879-3884 (2012).
7. Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176-181 (2014).
8. Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep. 6, 130-140 (2014).
9. Alizadeh, A.A. et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
10. Green, M.R. et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604-1611 (2013).
11. Green, M.R. et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA 112, E1116-E1125 (2015).
12. Shilatifard, A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81, 65-95 (2012).
13. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
14. Li, B., Carey, M. & Workman, J.L. The role of chromatin during transcription. Cell 128, 707-719 (2007).
15. Briggs, S.D. et al. Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae. Genes Dev. 15, 3286-3295 (2001).
16. Roguev, A. et al. The Saccharomyces cerevisiae Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4. EMBO J. 20, 7137-7148 (2001).
17. Miller, T. et al. COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc. Natl. Acad. Sci. USA 98, 12902-12907 (2001).
18. Krogan, N.J. et al. COMPASS, a histone H3 (lysine 4) methyltransferase required for telomeric silencing of gene expression. J. Biol. Chem. 277, 10753-10755 (2002).
19. Herz, H.M. et al. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev. 26, 2604-2620 (2012).
20. Hu, D. et al. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol. Cell. Biol. 33, 4745-4754 (2013).
21. Lee, J.E. et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. eLife 2, e01503 (2013).
22. Guo, C. et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 4, 2144-2153 (2013).
23. Kaikkonen, M.U. et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51, 310-325 (2013).
24. Ng, S.B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790-793 (2010).
25. Guo, C. et al. Global identification of MLL2-targeted loci reveals MLL2s role in diverse signaling pathways. Proc. Natl. Acad. Sci. USA 109, 17603-17608 (2012).
26. Santos, M.A. et al. DNA damage-induced differentiation of leukemic cells as an anti-cancer barrier. Nature 514, 107-111 (2014).
27. Dhar, S.S. et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev. 26, 2749-2762 (2012).
28. Casola, S. et al. Tracking germinal center B cells expressing germline immunoglobulin α1 transcripts by conditional gene targeting. Proc. Natl. Acad. Sci. USA 103, 7396-7401 (2006).
29. Rickert, R.C., Roes, J. & Rajewsky, K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317-1318 (1997).
30. Carsetti, R., Kohler, G. & Lamers, M.C. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181, 2129-2140 (1995).
31. Allman, D. et al. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J. Immunol. 167, 6834-6840 (2001).
32. Jacob, J. & Kelsoe, G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J. Exp. Med. 176, 679-687 (1992).
33. Lim, W.K., Lyashenko, E. & Califano, A. Master regulators used as breast cancer metastasis classifier. Pacific Symposium on Biocomputing 504-515 (2009).
34. Pao, L.I. et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27, 35-48 (2007).
35. Yokouchi, M., Suzuki, R., Masuhara, M., Komiya, S., Inoue, A. & Yoshimura, A. Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B cell receptor stimulation. Oncogene 15, 7-15 (1997).
36. Sauer, K. & Cooke, M.P. Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat. Rev. Immunol. 10, 257-271 (2010).
37. Liu, Y.J. et al. Mechanism of antigen-driven selection in germinal centers. Nature 342, 929-931 (1989).
38. Egle, A., Harris, A.W., Bath, M.L., OReilly, L. & Cory, S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276-2283 (2004).
39. Beguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
40. Zhang, J. et al. Genetic heterogeneity of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 110, 1398-1403 (2013).
41. Creyghton, M.P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931-21936 (2010).
42. Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279-283 (2011).
43. Whyte, W.A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013).
44. Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013).
45. Ardehali, M.B. et al. Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription. EMBO J. 30, 2817-2828 (2011).
46. Calo, E. & Wysocka, J. Modification of enhancer chromatin: what, how and why? Mol. Cell 49, 825-837 (2013).
47. Petruk, S. et al. TrxG and PcG proteins but not methylated histones remain associated with DNA through replication. Cell 150, 922-933 (2012).
48. Pasqualucci, L. The genetic basis of diffuse large B cell lymphoma. Curr. Opin. Hematol. 20, 336-344 (2013).
49. Pasqualucci, L. et al. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 40, 108-112 (2008).
50. Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B cell diffuse large-cell lymphomas. Nature 412, 341-346 (2001).
51. Hatzi, K. & Melnick, A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol. Med. 20, 343-352 (2014).
52. Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445-455 (2005).
53. Mandelbaum, J. et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18, 568-579 (2010).
54. Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
55. Knutson, S.K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
56. McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
57. Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl. Acad. Sci. USA 100, 2639-2644 (2003).
58. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B cell lymphoma. Nature 459, 717-721 (2009).
59. Dominguez-Sola, D. et al. The proto-oncogene is required for selection in the germinal center and cyclic reentry. Nat. Immunol. 13, 1083-1091 (2012).
60. Thomas, M. et al. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. USA 102, 5679-5684 (2005).
61. Bereshchenko, O.R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32, 606-613 (2002).
62. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-δδCT method. Methods 25, 402-408 (2001).
63. Green, M.R. & Sambrook, J. Molecular Cloning: A Laboratory Manual 4th edn. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA, 2012).
64. Jolly, C.J., Klix, N. & Neuberger, M.S. Rapid methods for the analysis of immunoglobulin gene hypermutation: application to transgenic and gene-targeted mice. Nucleic Acids Res. 25, 1913-1919 (1997).
65. Klein, U. et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 7, 773-782 (2006).
66. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
67. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289-300 (1995).
68. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J.P. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 23, 3251-3253 (2007).
69. Huang, D.W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
70. Blecher-Gonen, R. et al. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat. Protoc. 8, 539-554 (2013).
71. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
72. Li, H. et al. The sequence alignment-map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
73. Giannopoulou, E.G. & Elemento, O. An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinformatics 12, 277 (2011).
74. Lin, C.Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56-67 (2012).
75. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).